NASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Price, News & Analysis $7.85 -0.11 (-1.38%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$7.80 -0.05 (-0.70%) As of 03/28/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Zevra Therapeutics Stock (NASDAQ:ZVRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zevra Therapeutics alerts:Sign Up Key Stats Today's Range$7.77▼$7.9950-Day Range$7.33▼$8.3552-Week Range$4.20▼$9.76Volume211,539 shsAverage Volume590,075 shsMarket Capitalization$424.81 millionP/E RatioN/ADividend YieldN/APrice Target$22.29Consensus RatingBuy Company OverviewZevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.Read More… Remove Ads Zevra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreZVRA MarketRank™: Zevra Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 415th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZevra Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zevra Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.95) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zevra Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.40% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Zevra Therapeutics has recently decreased by 0.71%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.40% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Zevra Therapeutics has recently decreased by 0.71%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment1.18 News SentimentZevra Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Zevra Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for ZVRA on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have sold 746.95% more of their company's stock than they have bought. Specifically, they have bought $79,600.00 in company stock and sold $674,176.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.03% of the stock of Zevra Therapeutics is held by institutions.Read more about Zevra Therapeutics' insider trading history. Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ZVRA Stock News HeadlinesInsider Buying: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Buys 10,000 Shares of StockMarch 22, 2025 | insidertrades.comZevra Therapeutics management to meet with Cantor FitzgeraldMarch 26 at 4:52 AM | markets.businessinsider.comTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 29, 2025 | Porter & Company (Ad)Zevra Therapeutics (ZVRA) Projected to Post Earnings on ThursdayMarch 25, 2025 | americanbankingnews.comZevra Therapeutics Independent Director Acquires 33% More StockMarch 23, 2025 | finance.yahoo.comZevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 14, 2025 | finance.yahoo.comZevra Therapeutics’ Earnings Call Highlights Success and GrowthMarch 12, 2025 | tipranks.comZevra Therapeutics: Zevra Reports Full Year 2024 and Fourth Quarter Financial ResultsMarch 12, 2025 | finanznachrichten.deSee More Headlines ZVRA Stock Analysis - Frequently Asked Questions How have ZVRA shares performed this year? Zevra Therapeutics' stock was trading at $8.34 on January 1st, 2025. Since then, ZVRA shares have decreased by 5.9% and is now trading at $7.85. View the best growth stocks for 2025 here. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) released its quarterly earnings data on Tuesday, March, 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.28. The business earned $12 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative trailing twelve-month return on equity of 159.54%. Who are Zevra Therapeutics' major shareholders? Top institutional investors of Zevra Therapeutics include Woodline Partners LP (7.75%), Adage Capital Partners GP L.L.C. (6.84%), Vanguard Group Inc. (5.29%) and Nantahala Capital Management LLC (4.38%). Insiders that own company stock include Neil F Mcfarlane, John B Bode, Joshua Schafer, Thomas Anderson, Matthew R Plooster, Timothy J Sangiovanni, Corey Michael Watton and Tamara A Seymour. View institutional ownership trends. How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Tesla (TSLA). Company Calendar Last Earnings3/11/2025Today3/28/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZVRA CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$22.29 High Stock Price Target$25.00 Low Stock Price Target$18.00 Potential Upside/Downside+183.9%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,050,000.00 Net Margins-342.63% Pretax Margin-361.75% Return on Equity-159.54% Return on Assets-51.50% Debt Debt-to-Equity Ratio0.84 Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual Sales$23.61 million Price / Sales17.99 Cash FlowN/A Price / Cash FlowN/A Book Value$1.71 per share Price / Book4.59Miscellaneous Outstanding Shares54,116,000Free Float52,095,000Market Cap$424.81 million OptionableOptionable Beta1.98 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ZVRA) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.